Firm seeks funding ahead of taking Alzheimer's gene therapy into clinic

Tetraneuron, a Spanish biotech taking a multifactorial approach to Alzheimer's through gene therapy, is to start a new round of financing.

The Madrid-based spin-off from the Cajal-CSIC Institute, which was created a decade ago, is developing an advanced treatment through a therapeutic approach focused on E2F4, a protein involved in the origin of the mechanism of Alzheimer's pathogenesis.

José María Frade (pictured above with Carmen Álvarez), founding partner and scientific director of Tetraneuron, explained: “Tetraneuron has had to carry out extensive research work in order to demonstrate to the rest of the scientific community the role of our therapeutic target during the early stages of the disease pathogenesis mechanism. Thanks to the perseverance of the entire team, we have managed to define the AAV-E2F4DN gene therapy, which has shown a multifactorial therapeutic effect in mice models.”